Skip to main content

DESARROLLO DE COMPUESTOS PARA LA VALIDACION E IDENTIFICACION DE DIANAS TERAPEUTICAS MEDIANTE QUIMICA GENOMICA DIRECTA E INVERSA

SAF2010-22198-C02-01

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2010
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

New serotonin 5-HT1A receptor agonists with neuroprotective effect against ischemic cell damage

  • Marco, Isabel
  • Valhondo Falcón, Margarita
  • Martín-Fontecha Corrales, María Del Mar
  • Vázquez Villa, María Del Henar
  • Del Rio, Joaquin
  • Planas, Anna
  • Sagredo Ezquioga, Onintza
  • Ramos Atance, José Antonio
  • Torrecillas, Iván R.
  • Pardo, Leonardo
  • Frechilla, Diana
  • Benhamú Salama, Bellinda
  • López Rodríguez, María Luz
We report the synthesis of new compounds 4–35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT1A receptor (5-HT1AR). Computational β2-based homology models of the ligand–receptor complexes were used to explain the observed structure–affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4-dihydro-2H-chromen-2-ylmethyl)amino]hexyl}tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione) has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 5.9 nM, EC50 = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.
Docta Complutense
Publication Artículo científico (JournalArticle)

New inhibitors of angiogenesis with antitumor activity in vivo

  • Marín Ramos, Nagore I.
  • Alonso, Dulce
  • Ortega Gutiérrez, Silvia
  • Ortega Nogales, Francisco J.
  • Balabasquer, Moisés
  • Vázquez Villa, María Del Henar
  • Andradas, Clara
  • Blasco Benito, Sandra
  • Pérez Gómez, Eduardo
  • Canales Mayordomo, María Ángeles
  • Jiménez Barbero, Jesus
  • Marquina, Ana
  • Moscoso del Prado, Jaime
  • Sánchez García, María Cristina
  • Martín-Fontecha Corrales, María Del Mar
  • López Rodríguez, María Luz
Angiogenesis is a requirement for the sustained growth and proliferation of solid tumors, and the development of new compounds that induce a sustained inhibition of the proangiogenic signaling generated by tumor hypoxia still remains as an important unmet need. In this work, we describe a new antiangiogenic compound (22) that inhibits proangiogenic signaling under hypoxic conditions in breast cancer cells. Compound 22 blocks the MAPK pathway, impairs cellular migration under hypoxic conditions, and regulates a set of genes related to angiogenesis. These responses are mediated by HIF-1α, since the effects of compound 22 mostly disappear when its expression is knocked-down. Furthermore, administration of compound 22 in a xenograft model of breast cancer produced tumor growth reductions ranging from 46 to 55% in 38% of the treated animals without causing any toxic side effects. Importantly, in the responding tumors, a significant reduction in the number of blood vessels was observed, further supporting the mechanism of action of the compound. These findings provide a rationale for the development of new antiangiogenic compounds that could eventually lead to new drugs suitable for the treatment of some types of tumors either alone or in combination with other agents.
Docta Complutense
Publication Artículo científico (JournalArticle)

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

  • Valhondo Falcón, Margarita
  • Marco, Isabel
  • Martín-Fontecha Corrales, María Del Mar
  • Vázquez Villa, María Del Henar
  • Ramos Atance, José Antonio
  • Berkels, Reinhard
  • Lauterbach, Thomas
  • Benhamú Salama, Bellinda
  • López Rodríguez, María Luz
We report the synthesis of new compounds 4–35 based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3. The synthesized compounds were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR. Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro. Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy)ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (Ki = 2.3 nM; EC50 = 19 nM). Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ∼ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM). Interestingly, 19 (3 mg/kg, ip, and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635. Thus, the new 5-HT1AR agonist identified in this work, 19, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.
Docta Complutense
Publication Artículo científico (JournalArticle)

Effective GTP-replacing FtsZ inhibitors and antibacterial mechanism of action

  • Artola, Marta
  • Ruiz Ávila, Laura
  • Vergonos, Albert
  • Huecas, Sonia
  • Araujo Bazán, Lidia
  • Martín-Fontecha Corrales, María Del Mar
  • Vázquez Villa, María Del Henar
  • Turrado, Carlos
  • Ramírez Aportela, Erney
  • Hoegl, Annabelle
  • Nodwell, Matthew
  • Barasoain, Isabel
  • Chacón, Pablo
  • Sieber, Stephan A.
  • Andreu, Jose M.
  • López Rodríguez, María Luz
Essential cell division protein FtsZ is considered an attractive target in the search for antibacterials with novel mechanisms of action to overcome the resistance problem. FtsZ undergoes GTP-dependent assembly at midcell to form the Z-ring, a dynamic structure that evolves until final constriction of the cell. Therefore, molecules able to inhibit its activity will eventually disrupt bacterial viability. In this work, we report a new series of small molecules able to replace GTP and to specifically inhibit FtsZ, blocking the bacterial division process. These new synthesized inhibitors interact with the GTP-binding site of FtsZ (Kd = 0.4–0.8 μM), display antibacterial activity against Gram-positive pathogenic bacteria, and show selectivity against tubulin. Biphenyl derivative 28 stands out as a potent FtsZ inhibitor (Kd = 0.5 μM) with high antibacterial activity [MIC (MRSA) = 7 μM]. In-depth analysis of the mechanism of action of compounds 22, 28, 33, and 36 has revealed that they act as effective inhibitors of correct FtsZ assembly, blocking bacterial division and thus leading to filamentous undivided cells. These findings provide a compelling rationale for the development of compounds targeting the GTP-binding site as antibacterial agents and open the door to antibiotics with novel mechanisms of action.